Nidanib is more effective in the treatment of pulmonary fibrosis.
Nidanib can block the growth factor-related signaling pathway, inhibit the proliferation, migration and differentiation of fibroblasts, and then inhibit the deposition of collagen fibers, slowing down the process of pulmonary fibrosis, and can delay the progression of the disease by slowing down the rate of annual decline in lung function, such as exertion lung capacity, but there are also adverse reactions, and need to be used under the guidance of a doctor.
Therefore, patients with idiopathic pulmonary fibrosis can be treated with Nidazanib under the supervision of a doctor, which can help to alleviate the condition and avoid further progression of pulmonary fibrosis.
However, the specific condition of the patient is different, the use of drugs are also different, some patients may not be effective after taking the drug.
Nidazanib should be taken when taking the drug to pay attention to the drug ingredients allergy is prohibited, after taking the drug if there are serious adverse reactions, such as bleeding, high blood pressure, loss of appetite, etc., if necessary, the need to stop the drug and consult a doctor.